Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference (Q40811285)

23 September 2017

1 reference

title

Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference (English)

1 reference

23 September 2017

0 references

Ramsey BW

1

1 reference

23 September 2017

Boat TF

series ordinal

2

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 February 1994

1 reference

The Journal of Pediatrics

23 September 2017

published in

1 reference

23 September 2017

volume

124

1 reference

23 September 2017

issue

2

1 reference

23 September 2017

page(s)

177-192

1 reference

The changing epidemiology of cystic fibrosis

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Cystic fibrosis: molecular biology and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Identification of the cystic fibrosis gene: chromosome walking and jumping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Identification of the cystic fibrosis gene: genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Generation of cAMP-Activated Chloride Currents by Expression of CFTR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Aerosol α1 -antitrypsin treatment for cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Disposition of drugs in cystic fibrosis. III. Acetaminophen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Disposable jet nebulizers. How reliable are they?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Relationship between tracheobronchial particle clearance rates and sites of initial deposition in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Radioaerosol assessment of lung improvement in cystic fibrosis patients treated for acute pulmonary exacerbations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

A note on stratifying versus complete random assignment in clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Randomization in clinical trials: conclusions and recommendations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Factorial and reciprocal control designs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: A report from the cystic fibrosis genetic analysis consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

The relation between genotype and phenotype in cystic fibrosis--analysis of the most common mutation (delta F508).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Cystic fibrosis survival rates. The influences of allergy and Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Exposure of children with cystic fibrosis to environmental tobacco smoke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Airway hyperreactivity in cystic fibrosis. Clinical correlates and possible effects on the course of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Relative ion permeability of normal and cystic fibrosis nasal epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Changes in spirometry during consecutive admissions for infective pulmonary exacerbations in adolescent and adult cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Standardization of lung function testing in children. Proceedings and Recommendations of the GAP Conference Committee, Cystic Fibrosis Foundation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Oscillation mechanics of lungs and chest in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Moment analysis of multibreath lung washout

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Respiratory mechanics in infants: physiologic evaluation in health and disease. American Thoracic Society/European Respiratory Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Expiratory flow limitation in infants with bronchopulmonary dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Infants with cystic fibrosis: pulmonary function at diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Bronchial responsiveness to histamine in wheezy infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Bronchodilator responsiveness in infants and young children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

The prognostic value of exercise testing in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

The systematic evaluation of the chest radiograph in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

High resolution computed tomography in adult cystic fibrosis patients with mild lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Ultrafast computerized tomography of the chest in cystic fibrosis: a new scoring system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Cystic fibrosis: scoring system with thin-section CT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Quantitative deposition of aerosolized gentamicin in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

The Correlation of Radiological Changes with Pulmonary Function in Cystic Fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Predictive Value of Oropharyngeal Cultures for Identifying Lower Airway Bacteria in Cystic Fibrosis Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Selective media for the quantitation of bacteria in cystic fibrosis sputum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Workshop summary and guidelines: investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airway diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Granulocyte elastase-alpha 1-antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Combined evaluation of circulating immune complexes and antibodies to Pseudomonas aeruginosa as an immunologic profile in relation to pulmonary function in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Leukotrienes in the sputum and urine of cystic fibrosis children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Altered urinary excretion of elastin cross-links in premature infants who develop bronchopulmonary dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

New norms of upper limb fat and muscle areas for assessment of nutritional status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Physical growth: National Center for Health Statistics percentiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

A 5 YEAR CLINICAL EVALUATION OF A THERAPEUTIC PROGRAM FOR PATIENTS WITH CYSTIC FIBROSIS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

A new prognostic score and clinical evaluation system for cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Interobserver variance in clinical scoring for cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Ceftazidime therapy in patients with cystic fibrosis and multiply-drug-resistant pseudomonas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Assessment of quality of life in clinical trials of cardiovascular therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

The quality of well-being in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

Monitoring of clinical trials: issues and recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2894%2970301-9

10.1016/S0022-3476(94)70301-9

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference